

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

Director, Patent Examining Group The amendment filed on	APPLICATION NUMBER	LICATION NUMBER FILING DATE FIRST NAMED APPLICANT		ATTORNEY DOCKET NO.	
THE DUPONT MERCK PHARMACEUTICAL COMPANY E I DUPONT DE NEMOURS AND COMPANY LEGAL PATENTS 1007 MARKET STREET WILMINGTON DE 19898 Response to Rule 312 Communication Response to Rule 312 Communication The petition filed on	09/015,002	01/28/98 HE		L	DM-6864-A
MAUREEN P 0 BRIEN THE DUPONT MERCK PHARMACEUTICAL COMPANY E I DUPONT DE NEMOURS AND COMPANY LEGAL PATENTS 1007 MARKET STREET WILMINGTON DE 19898 Response to Rule 312 Communication Response to Rule 312 Communication The petition filed on				EXAMIN	IER :
THE DUPONT MERCK PHARMACEUTICAL COMPANY E I DUPONT DE NEMOURS AND COMPANY LEGAL PATENTS 1007 MARKET STREET 1624 #79 WILMINGTON DE 19898 Response to Rule 312 Communication The petition filed onunder 37 CFR 1.312(b) is granted. The paper has been forwarded to the examiner for consideration on the merits. Director, Patent Examining Group The amendment filed onunder 37 CFR 1.312 has been considered, and has been well entered. entered as directed to matters of form not affecting the scope of the invention (Order 3311). disapproved. See explanation below. entered in part. See explanation below.			'542/1214 ^v		
E I DUPONT DE NEMOURS AND COMPANY LEGAL PATENTS 1007 MARKET STREET WILMINGTON DE 19898 Response to Rule 312 Communication The petition filed on under 37 CFR 1.312(b) is granted. The paper has been forwarded to the examiner for consideration on the merits. Director, Patent Examining Group The amendment filed on under 37 CFR 1.312 has been considered, and has been we entered. entered as directed to matters of form not affecting the scope of the invention (Order 3311). disapproved. See explanation below. entered in part. See explanation below.			CAL COMPANY		
WILMINGTON DE 19898 Response to Rule 312 Communication The petition filed on under 37 CFR 1.312(b) is granted. The paper has been forwarded to the examiner for consideration on the merits. Director, Patent Examining Group entered. entered as directed to matters of form not affecting the scope of the invention (Order 3311). disapproved. See explanation below. entered in part. See explanation below.					Hic
Response to Rule 312 Communication The petition filed on under 37 CFR 1.312(b) is granted. The paper has been forwarded to the examiner for consideration on the merits. Director, Patent Examining Group entered. entered as directed to matters of form not affecting the scope of the invention (Order 3311). disapproved. See explanation below. entered in part. See explanation below.					#19
The petition filed on under 37 CFR 1.312(b) is granted. The paper has been forwarded to the examiner for consideration on the merits. Director, Patent Examining Group The amendment filed on under 37 CFR 1.312 has been considered, and has been entered. entered as directed to matters of form not affecting the scope of the invention (Order 3311). disapproved. See explanation below.	WICHING LON		D	ATE MAILED:	12/14/00
The amendment filed on under 37 CFR 1.312 has been considered, and has been considered. entered. entered as directed to matters of form not affecting the scope of the invention (Order 3311). disapproved. See explanation below. entered in part. See explanation below.	☐ The petition filed of forwarded to the e	on	under 37 CFR 1.312(ton the merits.	o) is granted. The	e paper has been
Don Marsh	entered. entered as dir disapproved. entered in par	ected to matters of form no See explanation below. t. See explanation below.	under 37 CFR 1.312	has been conside	ered, and has been:

Publishing Division